Disease · MONDO_0001382
hepatorenal syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hepatorenal syndrome. Diseases, record MONDO_0001382. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001382
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TERLIPRESSIN | CHEMBL2135460 | Protein | Approval | FDA | 22 | 21 | 21 | Drugs and targets |
| NOREPINEPHRINE | CHEMBL1437 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| METOPROLOL SUCCINATE | CHEMBL2356097 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBUMIN HUMAN | CHEMBL1201451 | Protein | Phase 2/3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| OCTREOTIDE | CHEMBL1680 | Protein | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| MIDODRINE | CHEMBL1201212 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PENTOXIFYLLINE | CHEMBL628 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZINC SULFATE | CHEMBL1200929 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANGIOTENSIN II | CHEMBL408403 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets46
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 2 | Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| AVPR1A | Vasopressin V1 receptor | 2 | Vasopressin V1 receptor binding agent; Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/552 | Drugs and targets |
| AVPR1B | Vasopressin V1 receptor | 2 | Vasopressin V1 receptor binding agent; Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/553 | Drugs and targets |
| AVPR2 | Vasopressin V2 receptor | 2 | Vasopressin V2 receptor binding agent; Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/554 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
1 to 10 of 46
See all 46 targetsTrials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02770716 | Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 | Phase 3 | 300 | 2022-08-18 | Hepatorenal Syndrome | TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01143246 | A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin | Phase 3 | 196 | 2022-11-29 | Hepatorenal Syndrome | TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01809132 | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis | Phase 2/3 | 104 | 2020-12-10 | Acute Alcoholic Hepatitis | ANAKINRA, PENTOXIFYLLINE, ZINC SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01436500 | Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients | Phase 2 | 55 | 2017-02-14 | Hepatorenal Syndrome | IFETROBAN | Its record names the disease | ClinicalTrials.gov |
| NCT04460560 | Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) | Phase 3 | 50 | 2024-10-09 | Hepatorenal Syndrome | TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov |
| NCT00886262 | Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant | Not applicable | 18 | 2018-10-17 | Liver Failure | VASOPRESSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01676285 | Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis | Phase 3 | 125 | Cirrhosis, Cirrhotic Cardiomyopathy, Cardiac Remodeling | METOPROLOL SUCCINATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05346393 | HRS-AKI Treatment With TIPS in Patients With Cirrhosis | Not applicable | 124 | Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic | ALBUMIN HUMAN, TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02573727 | To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure | Not applicable | 120 | Acute on Chronic Liver Failure | NOREPINEPHRINE, TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00089570 | Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 | Phase 3 | 112 | Hepatorenal Syndrome | TERLIPRESSIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Terlipressin vs Placebo: deaths from any cause | 101 of 200 | 45 of 99 | 299 | NCT02770716 | Trial comparisons |
| Terlipressin vs Placebo: serious adverse events | 142 of 200 | 62 of 99 | 299 | NCT02770716 | Trial comparisons |
| Terlipressin vs Placebo: deaths from any cause | 41 of 97 | 45 of 99 | 196 | NCT01143246 | Trial comparisons |
| Terlipressin vs Placebo: serious adverse events | 62 of 93 | 59 of 95 | 188 | NCT01143246 | Trial comparisons |
| Ifetroban vs Placebo: deaths from any cause | 7 of 42 | 2 of 13 | 55 | NCT01436500 | Trial comparisons |
| Ifetroban vs Placebo: serious adverse events | 21 of 42 | 8 of 13 | 55 | NCT01436500 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: Count of Patient Who Need Vasopressers in the Perioperative Period | 3 of 8 | 4 of 10 | 18 | NCT00886262 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: Count of Participants Who Needed Diuretics Postoperatively | 4 of 8 | 1 of 10 | 18 | NCT00886262 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: deaths from any cause | 0 of 8 | 0 of 10 | 18 | NCT00886262 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: serious adverse events | 0 of 8 | 0 of 10 | 18 | NCT00886262 | Trial comparisons |
Papers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 17560680 | RESULT | 2 | PubMed |
| 16393283 | RESULT | 1 | PubMed |
| 41200852 | DERIVED | 1 | PubMed |
| 40704461 | DERIVED | 3 | PubMed |
| 40658810 | DERIVED | 1 | PubMed |
| 38235907 | DERIVED | 1 | PubMed |
| 37302573 | DERIVED | 3 | PubMed |
| 37145232 | DERIVED | 1 | PubMed |
| 37143199 | DERIVED | 3 | PubMed |
| 37020315 | DERIVED | 1 | PubMed |
1 to 10 of 23
See all 23 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001382
GET https://conductscience.org/api/diseases/v1/MONDO_0001382/targets?page=2